Melina Elpi Marmarelis, MD

Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Medical Director of Penn Medicine Mesothelioma and Pleural Program, University of Pennsylvania
PC3I Faculty, Penn Center for Cancer Care Innovation, University of Pennsylvania
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
10th Floor
Philadelphia, PA 19104
3400 Civic Center Blvd
10th Floor
Philadelphia, PA 19104
Education:
BA (Bachelors in Biochemistry and Molecular Biology )
Dartmouth College, 2007.
MD (Medicine)
Harvard Medical School , 2013.
MSCE (Clinical Epidemiology )
University of Pennsylvania , 2019.
Permanent linkBA (Bachelors in Biochemistry and Molecular Biology )
Dartmouth College, 2007.
MD (Medicine)
Harvard Medical School , 2013.
MSCE (Clinical Epidemiology )
University of Pennsylvania , 2019.
Description of Clinical Expertise
Lung cancer and mesothelioma.Description of Research Expertise
Clinical trials in lung cancer in mesothelioma.Selected Publications
Se-Hoon Lee, Byoung Chul Cho, Alexander I. Spira, Sai-Hong Ignatius Ou, Saiama N. Waqar, Sujay Shah, Leonardo Trani, Pei-Ling Chu, Meena Thayu, Roland E. Knoblauch, Joshua M. Bauml, Melina E. Marmarelis : Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in Post-TKI EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2. IASLC world lung conference, oral presentation September 2023.Nikhil Yegya-Raman, Abigail T. Berman, Christine A. Ciunci, Cole Friedes, Eva Berlin, Michelle Iocolano, Xingmei Wang, Ching Lai, William P. Levin, Keith A. Cengel, Shannon E. O'Reilly, Roger B. Cohen, Charu Aggarwal, Melina E. Marmarelis, Aditi P. Singh, Lova Sun, Jeffrey D. Bradley, John P. Plastaras, Charles B. Simone II MD, Corey J. Langer, Steven J. Feigenberg: Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer: Pembro after PBT ReRT for NSCLC. International Journal of Radiation Oncology*Biology*Physics August 2023.
Charu Aggarwal, Melina E Marmarelis, Wei-Ting Hwang, Dylan G Scholes, Tara L McWilliams, Aditi P Singh, Lova Sun, John Kosteva, Michael R Costello, Roger B Cohen, Corey J Langer, Abigail Doucette, Peter N Gabriel, Lawrence N Shulman, Katharine A Rendle, Jeffrey C Thompson, Justin E Bekelman, Erica L Carpenter: Association between availability of molecular genotyping results and overall survival in patients with advanced non-squamous non-small cell lung cancer. JCO Precision Oncology Page: e2300191, July 2023.
L. Sun, M. Marmarelis, C. Aggarwal: Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed? Journal of Thoracic Oncology May 2023.
Nikhil Yegya-Raman, Cole Friedes, Lova Sun, Michelle Iocolano, Kristine N. Kim, Abigail Doucette, Roger B. Cohen, Kyle W. Robinson, William P. Levin, Keith A. Cengel, Brian Lally, Manuj Agarwal, Christopher A. D'Avella, Melina E. Marmarelis, John A. Kosteva, Aditi P. Singh, Christine A. Ciunci, Charu Aggarwal, Abigail T. Berman, Corey J. Langer, Steven J. Feigenberg: Utilization and factors precluding receipt of checkpoint inhibitor consolidation for stage III NSCLC in a large U.S. academic health system. Clinical Lung Cancer April 2023.
P. Bou-Samra, A. Chang, F. Azari, G. Kennedy, A. Segil, E. Guo, M. Marmarelis, C. Langer, S. Singhal : Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Medicine March 2023.
Mohsin Shah, Ronac Mamtani, Melina E. Marmarelis, Sean Hennessy: Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90% Clinical Lung Cancer March 2023.
Melina E. Marmarelis, MD, MSCE1; Xiao Wang, MD1; Leonid Roshkovan, MD2; Connor B. Grady, MPH3; John T. Miura, MD4; Michelle S. Ginsberg, MD5; Christine A. Ciunci, MD1; Jacklynn Egger, BS6; Suzanne Walker, PhD, CRNP1; Andrea Cercek, MD7; Michael B. Foote, MD7; Leslie A. Litzky, MD8; Garrett Nash, MD, MPH9; Andrew R. Haas, MD, PhD10; Giorgos C. Karakousis, MD4; Keith A. Cengel, MD, PhD11; Sharyn I. Katz, MD2; Marjorie G. Zauderer, MD6,12; Corey J. Langer, MD1; Michael Offin, MD6,12: Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open March 2023.
Marmarelis ME, Sun L, Aggarwal C: Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor. Journal of Thoracic Oncology March 2023.
Wade T. Iams, Meridith L. Balbach, Sharon Phillips, Adrian Sacher, Christine Bestvina, Vamsidhar Velcheti, Xiao Wang, Melina E. Marmarelis, Nan Sethakorn, Ticiana Leal, Paul E. Sackstein, Chul Kim, MD Andrew Robinson, Kathan Mehta, Robert Hsu, Jorge Nieva, Tejas Patil, D. Ross Camidge: A multi-center retrospective chart review of clinical outcomes among patients with KRAS G12C mutant non-small cell lung cancer. Clinical Lung Cancer February 2023.